A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance
Status:
Active, not recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
A multicenter, open-label, single-arm study with regard to the efficacy and safety of
empagliflozin in patients with refractory diabetes mellitus with insulin resistance